Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children after initiation of antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 33, Issue 9, 2014, Pages 953-958

  Gkentzi, Despoina ^a   Tebruegge, Marc ^b,c,d,e   Tudor Williams, Gareth ^b,f   Walters, Sam ^b,f   Lyall, Hermione ^b,f   Sharland, Mike ^g   Doerholt, Katja ^g  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy; BCG; HIV; Immune reconstitution syndrome; Tuberculosis

Indexed keywords

ABACAVIR; ACICLOVIR; AMIKACIN; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CIPROFLOXACIN; DAPSONE; EFAVIRENZ; ETHAMBUTOL; FOSCARNET; GANCICLOVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; NEVIRAPINE; PREDNISOLONE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TENOFOVIR; ZIDOVUDINE; BCG VACCINE;

ANTIVIRAL THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CHILD; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM BOVIS BCG; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TUBERCULOSIS; COMBINATION DRUG THERAPY; HIV INFECTIONS; IMMUNOLOGY; INCIDENCE; INFANT; LYMPHADENITIS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PRESCHOOL CHILD; SKIN DISEASES, VIRAL; TUBERCULOSIS, PULMONARY;

ANTI-RETROVIRAL AGENTS; BCG VACCINE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HERPES SIMPLEX; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFANT; LYMPHADENITIS; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; SKIN DISEASES, VIRAL; TUBERCULOSIS, PULMONARY;

EID: 84926166330     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000331     Document Type: Article

References (35)

1. Judd A, Doerholt K, Tookey PA, et al.; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC). Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918-924.
2. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300.
3. Kaufmann GR, Zaunders J, Cooper DA. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect. 1999;75:218-224.
4. Sleasman JW, Nelson R P, Goodenow MM, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr. 1999;134:597-606.
5. Manabe YC, Campbell JD, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46:456-462.
6. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10:417-422.
7. Lortholary O, Fontanet A, Mémain N, et al.; French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043-1049.
8. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 2003;5:67-79.
9. Michelet C, Arvieux C, François C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12:1815-1822.
10. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418-427.
11. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012;157:313-324.
12. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213-227.
13. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167-170.
14. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol. 2004;113:742-746.
15. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007;11:417-423.
16. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J. 2006;25:53-58.
17. Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis. 2005;41:1049-1052.
18. Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J. 2006;25:645-648.
19. Rabie H, Violari A, Duong T, et al.; CHER team. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15:1194-200, i.
20. Orikiiriza J, Bakeera-Kitaka S, Musiime V, et al. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS. 2010;24:2009-2017.
21. Gibb DM, Duong T, Tookey PA, et al.; National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
22. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1:107-115.
23. Jevtović DJ, Salemović D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005;6:140-143.
24. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601-610.
25. Nesheim SR, Hardnett F, Wheeling JT, et al.; LEGACY Consortium. Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children. Pediatr Infect Dis J. 2013;32:1089-1095.
26. Prosser AT, Tang T, Hall HI. HIV in persons born outside the United States, 2007-2010. JAMA. 2012;308:601-607.
27. Alexander A, Rode H. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants. J Pediatr Surg. 2007;42:549-552.
28. Deeks SL, Clark M, Scheifele DW, et al. Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada. Pediatr Infect Dis J. 2005;24:538-541.
29. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23:476-479.
30. Ritz N, Tebruegge M, Connell TG, et al. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53:316-318.
31. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004;39:1709-1712.
32. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006;53:357-363.
33. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-1501.
34. Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther. 2006;4:469-478.
35. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381-2390.